We are live on ! Find out more
RFL icon

Rafael Holdings

1.04 USD
-0.02
1.89%
At close Updated Nov 6, 4:00 PM EST
1 day
-1.89%
5 days
-3.7%
1 month
-30.2%
3 months
-48.51%
6 months
-16.8%
Year to date
-17.46%
1 year
-20%
5 years
-85.79%
10 years
-78.47%
 

About: Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Employees: 17

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 6.3%
Neutral 93.8%
Negative 0%
Neutral
PRNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
GlobeNewsWire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
GlobeNewsWire
4 days ago
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
NEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Monday, November 9, 2026 at 3:55 p.m. ET, and host one-on-one meetings with institutional investors.
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Neutral
PRNewsWire
9 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
GlobeNewsWire
9 days ago
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
9 days ago
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
NDA supported by the Phase 3 TransportNPC ™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
Neutral
GlobeNewsWire
10 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
PRNewsWire
16 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or  the "Company") (NYSE: RFL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
GlobeNewsWire
17 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Neutral
PRNewsWire
23 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Price charts implemented using Lightweight Charts™